Showing results (551-560 of 657) with videos related to

Sort By:
Pageof 66
Plos One|May 16, 2015
Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control StudyAdela Castelló, Miguel Martín, Amparo Ruiz, et al.
Gynecologic Oncology|January 7, 2017
Physical activity and breast cancer risk by pathological subtypeVirginia Lope, Miguel Martín, Adela Castelló, et al.
Drugs & Aging|February 23, 2021
Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's SyndromeSoledad Retamozo, Chiara Baldini, Hendrika Bootsma, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2021
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuationNoémie Chanson, Manuel Ramos-Casals, Xerxes Pundole, et al.
European Journal of Clinical Nutrition|February 23, 2022
Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM studyCarolina Donat-Vargas, Ángel Guerrero-Zotano, Virginia Lope, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|April 12, 2017
Executive summary of imported infectious diseases after returning from foreign travel: Consensus document of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)José Luis Pérez-Arellano, Miguel Górgolas-Hernández-Mora, Fernando Salvador, et al.
Plos Neglected Tropical Diseases|March 24, 2021
Chagas disease screening in pregnant Latin American women: Adherence to a systematic screening protocol in a non-endemic countryJara Llenas-García, Philip Wikman-Jorgensen, Concepción Gil-Anguita, et al.
The Oncologist|January 21, 2015
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysisMiguel Martín, Noelia Martínez, Manuel Ramos, et al.
The Lancet. Oncology|March 25, 2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyMiguel Martin, Henri Roche, Tamas Pinter, et al.
Malaria Journal|May 9, 2021
Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countriesNicolas Vignier, Olivier Bouchaud, Andrea Angheben, et al.
Pageof 66